Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kimberly A. Tipton
Observed name:
Kimberly Tipton
Institution:
ALX Oncology Inc. (United States)
Observed institutions:
QB3,
Howard Hughes Medical Institute,
University of California, San Francisco,
CytomX Therapeutics (United States),
CRISPR Therapeutics (Switzerland),
ALX Oncology Inc. (United States),
The University of Texas at Austin
show all 7
ORCID:
0000-0002-3051-1464
Observed ORCID:
0000-0002-3051-1464
OpenAlex ID:
A5059504850
In Vivo Monitoring of the Prion Replication Cycle Reveals a Critical Role for Sis1 in Delivering Substrates to Hsp104
2008
·
Kimberly A. Tipton
, Katherine J. Verges
, et al.
·
Molecular Cell
·
163
PDF
Directed Evolution of Substrate-Optimized GroEL/S Chaperonins
2002
·
Jue D. Wang
, Christophe Herman
, et al.
·
Cell
·
148
PDF
Shigella dysenteriaeShuS Promotes Utilization of Heme as an Iron Source and Protects against Heme Toxicity
2005
·
Elizabeth E. Wyckoff
, Gregory F. Lopreato
, et al.
·
Journal of Bacteriology
·
69
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2022
·
Shweta Singh
, Laura Serwer
, et al.
·
Molecular Cancer Therapeutics
·
46
PDF
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
2021
·
Iñaki Etxeberria
, Elixabet Bolaños
, et al.
·
Proceedings of the National Academy of Sciences
·
42
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016
·
Casey Ager
, Matthew Reilley
, et al.
·
Journal for ImmunoTherapy of Cancer
·
17
PDF
Abstract SY09-01: Next-generation anti-CTLA-4 antibodies
2017
·
Alan J. Korman
, John Engelhardt
, et al.
·
Cancer Research
·
13
CD70 is a potential target biomarker in peripheral T‐cell lymphomas
2022
·
Mario L Marques‐Piubelli
, Jason Sagert
, et al.
·
Histopathology
·
9
Abstract 4551: Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index
2020
·
John Engelhardt
, Rahima Akter
, et al.
·
Cancer Research
·
8
CD70 Expression in Mature T-Cell Lymphomas
2021
·
Mario L. Marques-Piubelli
, Luisa Solis Soto
, et al.
·
Blood
·
7
Abstract 3211: PD-1-targeted Probody therapeutics provide anti-tumor efficacy and a 10-fold dose protection against systemic autoimmunity in preclinical studies
2016
·
Kimberly A. Tipton
, Chanty Chan
, et al.
·
Cancer Research
·
4
Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.
2024
·
Samuel A Funt
, Petros Grivas
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors
2019
·
Yimao Liu
, Rui Wu
, et al.
·
Cancer Research
·
2
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023
·
Shweta Singh
, Laura Serwer
, et al.
PDF
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023
·
Shweta Singh
, Laura Serwer
, et al.
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023
·
Shweta Singh
, Laura Serwer
, et al.
Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors
2019
·
Yimao Liu
, Rui Wu
, et al.
·
Experimental and Molecular Therapeutics
Ordering the pathway of prion propagation in yeast through a structure/function analysis of Hsp104
2008
·
Kimberly Tipton
·
eScholarship (California Digital Library)
Show more works
View as search
Works count:
19
Citation count:
548
H-index:
9
I10-index:
8
Year
Topic
Type
